Menu
X
doctor.huang@globecancer.com Become Our Partner Get Free Help

Hematological Neoplasms

image
China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting

**China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting** #CSCO #CSCO2024 #Lymphoma #CART #LBCL #RRLBCL #ChinaCAR-T At the 27th Annual Chinese Society of Clinical Oncology (CSCO) Conference, held in Xiamen, China, CAR-T therapy took center stage as a key focus for the treatment of large B-cell lymphoma Read More

October 14th,2024 Lymphoma
image
Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL

**Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL** #CAR-TTherapy #TALL #ALL #Leukemia #RelapsedLeukemia #TCellLeukemia #CD5 #CD7 #CART Recently, a collaborative research study conducted by multiple Chinese medical and research institutions was published in *Nature Medicine*. This study, titled “Allogeneic CD5-specific CAR-T Therapy for Relapsed/Refractory T-ALL: A Phase 1 Read More

October 12th,2024 Leukemia
image
Blood Cancer – Diagnosis and Treatment Tips

Blood Cancer – Diagnosis and Treatment Tips #leukemia #multiplemyeloma #lymphoma Blood cancer, encompassing types such as leukemia, lymphoma, and multiple myeloma, represents a significant health challenge in regions like Southeast Asia and India. These hematologic malignancies arise from blood-forming cells and can impact the bone marrow, blood, and various organs. The increasing prevalence of these Read More

October 9th,2024 Hematological Neoplasms
image
**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient** #MultipleMyeloma #CARTtherapy #BloodCancer #CompleteRemission #CART       Multiple Myeloma (MM) is a malignant blood disorder characterized by abnormal proliferation of plasma cells, which causes damage to vital organs. Patients with high-risk cytogenetic abnormalities like 17p deletion, t(4;14) translocation, and t(14;16) translocation face an even worse prognosis. Read More

October 3rd,2024 Myeloma
image
BCMA CAR-T Therapy Paves New Path for Treating High-Risk Multiple Myeloma

**BCMA CAR-T Therapy Paves New Path for Treating High-Risk Multiple Myeloma** Multiple Myeloma (MM) is a malignant tumor originating from plasma cells, known for its complex biology and treatment resistance, presenting significant challenges to patients’ survival. For high-risk MM, especially in cases of relapse and refractory disease after multiple lines of therapy, treatment options become Read More

September 30th,2024 Myeloma
Recent Posts

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.